Skip to main content
PROF logo

PROF · Profound Medical Corp. · Webcasts, Transcripts & Audio

Track PROF — free
$6.38 -0.21 (-3.19%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$233.68M
Shares
36.63M
Volume · Nov 20 144.19K Avg daily vol (3M) 206.49K

Profound Medical Corp. Webcasts

Earnings calls, investor updates, investor days and conferences for Profound Medical Corp. (PROF), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Conference
Investor event
2026-11-12
Profound Medical Corp. (PROF) November 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q3
2026-11-05
Profound Medical Corp. (PROF) Q3 2026 Earnings Call Transcript
Confident tone Financial growth and guidance Clinical differentiation and evidence Cook Medical partnership
Revenue
$9.83M
▲ 85.9% YoY
Diluted EPS
$-0.21
Gross margin
78.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-08-06
Profound Medical Corp. (PROF) Q2 2026 Earnings Call Transcript
Confident tone Tulsa clinical evidence and CAPTAIN trial Commercial momentum and sales pipeline Reimbursement and payer coverage expansion
Revenue
$2.48M
▲ 12.3% YoY
Diluted EPS
$-0.26
Gross margin
78.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-07
Profound Medical Corp. (PROF) Q1 2026 Earnings Call
Revenue
$5.34M
▲ 103.6% YoY
Diluted EPS
$0.19
▼ 47.2% YoY
Gross margin
71.8%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
Profound Medical Corp. (PROF) Q4 2025 Earnings Call Transcript
Confident tone CAPTAIN trial and clinical evidence Revenue growth and financials Installed base growth and utilization targets
Revenue
$5.98M*
▲ 43.1% YoY
Gross margin
66.8%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-07
Profound Medical Corp. (PROF) Q3 2025 Earnings Call Transcript
Confident tone TULSA-AI Volume Reduction software launch BPH market expansion Revenue growth and profitability trajectory
Revenue
$5.29M
▲ 86.8% YoY
Diluted EPS
$-0.26
▼ 168.4% YoY
Gross margin
74.3%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript
Positive tone Software upgrade / procedure time CAPTAIN trial milestones Sales pipeline and funnel
Revenue
$2.21M
▼ 1% YoY
Diluted EPS
$-0.52
▼ 285.7% YoY
Gross margin
73.2%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Profound Medical Corp. (PROF) Q1 2025 Earnings Call Transcript
Confident tone TULSA-PRO clinical differentiation and CAPTAIN trial TULSA+ bundled offering with MRI partners Pipeline of cancer centers and adoption cycle
Revenue
$2.62M
▲ 82.1% YoY
Diluted EPS
$0.36
▲ 33.3% YoY
Gross margin
70.7%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Capital Markets Day
Investor event
2025-04-28
Profound Medical Corp. (PROF) April 28, 2025 Capital Markets Day Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY24 · Q4
2025-03-07
Profound Medical Corp. (PROF) Q4 2024 Earnings Call Transcript
Confident tone TULSA-PRO technology and precision Commercial organization and capital sales model Reimbursement and Medicare payments
Revenue
$4.18M*
Gross margin
70.9%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Date not confirmed
Profound Medical Corp. (PROF) Q3 2024 Earnings Call Transcript
Confident tone TULSA procedure and clinical flexibility Reimbursement and CPT Category 1 codes CAPTAIN clinical trial
Revenue
$2.83M
Diluted EPS
$0.38
Gross margin
63.1%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Date not confirmed
Profound Medical Corp. (PROF) Q2 2024 Earnings Call Transcript
Positive tone Real-world TULSA utilization Reimbursement and CPT codes Procedure throughput and economics
Revenue
$2.23M
Diluted EPS
$0.28
Gross margin
63.6%
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Date not confirmed
Profound Medical Corp. (PROF) Q1 2024 Earnings Call Transcript
Confident tone Recurring revenue and utilization growth Indication breadth and patient spectrum Reimbursement and CMS pricing
Revenue
$1.44M
Diluted EPS
$0.27
Gross margin
60.2%
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Date not confirmed
Profound Medical Corp. (PROF) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Date not confirmed
Profound Medical Corp. (PROF) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-06-30
Date not confirmed
Profound Medical Corp. (PROF) Q2 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Date not confirmed
Profound Medical Corp. (PROF) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Date not confirmed
Profound Medical Corp. (PROF) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-09-30
Date not confirmed
Profound Medical Corp. (PROF) Q3 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Date not confirmed
Profound Medical Corp. (PROF) Q2 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-03-31
Date not confirmed
Profound Medical Corp. (PROF) Q1 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Date not confirmed
Profound Medical Corp. (PROF) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Date not confirmed
Profound Medical Corp. (PROF) Q3 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Date not confirmed
Profound Medical Corp. (PROF) Q2 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Date not confirmed
Profound Medical Corp. (PROF) Q1 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Date not confirmed
Profound Medical Corp. (PROF) Q4 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Date not confirmed
Profound Medical Corp. (PROF) Q3 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Date not confirmed
Profound Medical Corp. (PROF) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Date not confirmed
Profound Medical Corp. (PROF) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–29 of 29 webcasts
Key facts CIK 1628808 CUSIP 74319B502 13F (30d) 58 filings 55 filers Visit website Investor relations